• CVS Health recently reported fourth-quarter 2025 results showing sales of US$34.02 billion and net income of US$2.94 billion, alongside record full-year revenue of US$402.07 billion but lower annual net income of US$1.77 billion due to goodwill and litigation charges.
• The company also confirmed 2026 GAAP diluted EPS guidance of US$5.94–US$6.14 and highlighted progress on its cost-based pharmacy reimbursement model and Rite Aid integration as it continues its turnaround efforts.
• Now we’ll examine how CVS Health’s earnings beat and reaffirmed 2026 guidance affect the existing investment narrative around its earnings recovery.

Find 53 companies with promising cash flow potential yet trading below their fair value.

CVS Health Investment Narrative Recap

To own CVS Health, I think you need to believe its integrated model can convert today’s low margins into steadier earnings across insurance, pharmacy, and care delivery. The latest quarter’s earnings beat and reaffirmed 2026 GAAP EPS guidance of US$5.94–US$6.14 support the near term earnings recovery story, while the biggest ongoing risk remains pressure on medical costs and margins in health care delivery rather than any new issue from this update.

The most relevant update here is management’s confirmation of 2026 EPS guidance alongside progress on its cost based pharmacy reimbursement model. By emphasizing that the TrueCost and CostVantage approaches are now in place and aligned with recent PBM reforms, CVS is trying to stabilize a key earnings driver, which directly ties into the short term catalyst of margin recovery in Aetna and the pharmacy businesses while it absorbs prior goodwill and litigation charges.

But while the turnaround is gaining traction, persistent pressure on medical benefit ratios in health care delivery is something investors should be aware of...

CVS Health's narrative projects $445.1 billion revenue and $8.3 billion earnings by 2028. This requires 5.0% yearly revenue growth and about a $3.8 billion earnings increase from $4.5 billion today.

Uncover how CVS Health's forecasts yield a $94.76 fair value, a 21% upside to its current price.

Exploring Other Perspectives

Six fair value estimates from the Simply Wall St Community span roughly US$94.76 to US$289.13, showing how far apart individual views can be. Against that wide range, the company’s need to improve thin 0.4 percent net margins and health care delivery profitability gives you a concrete set of issues to weigh as you explore those different perspectives.

Explore 6 other fair value estimates on CVS Health - why the stock might be worth over 3x more than the current price!

Build Your Own CVS Health Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your CVS Health research is our analysis highlighting 3 key rewards and 4 important warning signs that could impact your investment decision.
• Our free CVS Health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate CVS Health's overall financial health at a glance.

Ready For A Different Approach?

Early movers are already taking notice. See the stocks they're targeting before they've flown the coop:

• Outshine the giants: these 28 early-stage AI stocks could fund your retirement.
• Invest in the nuclear renaissance through our list of 85 elite nuclear energy infrastructure plays powering the global AI revolution.
• Explore 23 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.